News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Basilea Pharmaceutica Reports 2006 Interim Results Reflecting Successful Investment In Late-stage Development Programs
August 24, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BASEL, Switzerland, Aug. 24, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) reports interim financial results. Three compounds planned to be in phase III by year-end.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Earnings
Europe
MORE ON THIS TOPIC
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
·
3 min read
·
Gabrielle Masson
Earnings
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
July 27, 2026
·
3 min read
·
Tristan Manalac
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
July 27, 2026
·
10 min read
·
Heather McKenzie
